Abstract:Introduction: A primary impediment to the efficacy of immune checkpoint inhibitors is the lack of biomarkers for therapeutic responses and prognosis. Although patients with clear cell renal cell carcinoma (ccRCC) could be precisely selected for targeted therapy based on somatic mutations, it remains controversial to choose the suitable patients with a high response rate to immune checkpoint inhibitors (ICIs). The immune-dependent roles of tumor suppressor PTEN in the formation of tumor immune microenvironment remain elusive. Methods: We comprehensively analyzed the genomic and transcriptomic data from multiple ccRCC datasets, including bulk-RNA sequencing and single-cell RNA sequencing data. In vitro, immunoblotting, qRT-PCR, and RNA sequencing were conducted in ccRCC cell lines upon PTEN depletion. Gene ontology and gene set enrichment analysis were performed to screen the critical pathway and molecules in response to PTEN deletion. Immunohistochemistry staining and further bioinformatic analysis were used to validate our data. Results: Based on multi-omics analysis of public datasets of renal cancer, the frequently mutated or deleted PTEN was found to be correlated with a suppressive tumor immune microenvironment in ccRCC. Furthermore, we depleted PTEN via CRISPR-Cas9 in Caki-1 cells, which led to the upregulation of multiple neutrophil chemokines, particularly CXCL1, CXCL2, CXCL5, CXCL6, and CXCL8. The roles of neutrophil chemokines and neutrophil markers were further validated and investigated for the association with prognosis in vitro, clinical samples, and the publicly available databases. The expression of CXCL1, CXCL8, and neutrophil markers, S100A9 and BCL2A1, were significantly associated with a poor immunotherapy-related prognosis in public dataset of renal cancer patients receiving ICIs treatment. Conclusion: These results add a new layer to understanding the association between PTEN status and the role of neutrophil infiltration in ccRCC. Moreover, our findings propose low expression of PTEN as candidate factor of resistance to anti-PD-1-based immunotherapy in ccRCC.

Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells

The Clinical Significance of PTEN Protein Expression in Colorectal Carcinoma

Mutations of PTEN Gene in 117 Chinese Patients with Malignant Melanoma and Their Clinical Significance

PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma

Myeloid PTEN Promotes Chemotherapy-Induced NLRP3-inflammasome Activation and Antitumour Immunity

Regulation of the tumor suppressor PTEN by natural anticancer compounds

PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis

PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway

Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression

Exosome–transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression

Decoding PTEN: from biological functions to signaling pathways in tumors

Clinical significance of tumor suppressor PTEN in colorectal carcinoma

The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage

PTENα functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer

Investigate the Role of PTEN in Chemotaxis of Human Breast Cancer Cells.

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway

P2.02-020 Molecular Characteristics of Patients with PTEN Mutations in Chinese Non-Small Cell Lung Cancer

The Infiltration of Neutrophil Granulocytes Due to Loss of PTEN Was Associated with Poor Response to Immunotherapy in Renal Cell Carcinoma

PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK